Valuation — not yet established
No valuation for 4D Molecular Therapeutics is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($165.0M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for 4D Molecular Therapeutics
Create free account
No card required
Funding history
4 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Jun 2020 | Later Stage VC (Series C) | $75.0M | ▮ | ▮ |
| Sep 2018 | Early Stage VC (Series B) | $90.0M | ▮ | ▮ |
| Oct 2015 | Early Stage VC | $11.6M | ▮ | ▮ |
| Aug 2015 | Early Stage VC | $7.0M | ▮ | ▮ |
How 4D Molecular Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For 4D Molecular Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has 4D Molecular Therapeutics raised?
- 4D Molecular Therapeutics has raised $165.0M in total funding across 4 recorded rounds.
- When did 4D Molecular Therapeutics last raise?
- 4D Molecular Therapeutics last raised in Jun 2020 (Later Stage VC (Series C)), raising $75.0M.